Asparkam-L, 45.2mg/ml+40 mg/ml 5 ml 10 pcs

The mechanism of action of Asparkam is related to effective participation of L-asparaginate in transport of magnesium and potassium ions into intracellular space.Magnesium activates sodium-potassium-ATPase, removing sodium ions from cell and returning potassium ions; reduces sodium concentration and prevents its exchange for calcium in vascular smooth muscles, reducing their resistance. Potassium stimulates the synthesis of ATP, glycogen, proteins, acetylcholine, etc.

The two ions support the polarization of cell membranes.

The drug regulates the conduction of impulses along the nerve fibers, synaptic transmission, muscle contraction, and the work of the heart muscle. Due to magnesium ions the product participates in the processes of energy input and output, normalizes membrane permeability, neuromuscular conduction, DNA and RNA synthesis, cell growth, cell division, oxygen assimilation and phosphate synthesis.

Indications

To eliminate potassium and magnesium deficiency;
as an adjuvant for various manifestations of coronary heart disease, including acute myocardial infarction;
chronic circulatory failure;
heart rhythm disturbances (arrhythmias caused by an overdose of cardiac glycosides).

Pharmacological effect

The mechanism of action of the drug Asparkam is associated with the effective participation of L-aspartate in the transport of magnesium and potassium ions into the intracellular space. Magnesium activates sodium-potassium ATPase, removing sodium ions from the cell and returning potassium ions; reduces sodium concentration and prevents its exchange for calcium in vascular smooth muscles, reducing their resistance. Potassium stimulates the synthesis of ATP, glycogen, proteins, acetylcholine, etc.

Both ions support the polarization of cell membranes.

The drug regulates the conduction of impulses along nerve fibers, synaptic transmission, muscle contraction, and the functioning of the heart muscle. Due to magnesium ions, it participates in the processes of energy intake and expenditure, normalizes membrane permeability, neuromuscular conduction, DNA and RNA synthesis, cell growth, cell division, oxygen uptake and phosphate synthesis.

Special instructions

No studies have been conducted to assess the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Potassium aspartate, Magnesium aspartate

Composition

1 ml of solution for intravenous administration contains:

active ingredients:

magnesium aspartate anhydrous 40 mg (magnesium content – 3.37 mg),

potassium aspartate anhydrous 45.2 mg (potassium content – 10.33 mg);

excipients:

sorbitol (sorbitol),

water for injections.

Contraindications

Hypersensitivity to the drug Asparkam,
hyperkalemia,
hypermagnesemia,
acute and chronic renal failure,
adrenal insufficiency,
atrioventricular block II and III degrees,
cardiogenic shock,
oliguria – anuria,
acute metabolic acidosis,
myasthenia gravis,
dehydration, Addison’s disease,
arterial hypotension,
pregnancy,
lactation period,
age under 18 years (efficacy and safety have not been established).

Side Effects

Possible nausea, dizziness,
facial redness,
thirst,
decreased blood pressure, hyporeflexia.
hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnesemia (facial skin hyperemia, thirst, bradycardia, decreased blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions);
with parenteral administration – atrioventricular block, paradoxical reaction (increased number of extrasystoles), phlebitis.
with rapid intravenous administration, all symptoms of hyperkalemia and hypermagnesemia may appear.

Interaction

Potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs – the risk of developing hyperkalemia up to the development of arrhythmia and asystole.

Eliminates hypokalemia caused by glucocorticosteroids.

Reduces the undesirable effects of cardiac glycosides.

Due to the content of magnesium ions, it reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.

Anesthetics enhance the inhibitory effect of magnesium on the central nervous system.

May enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracurium besylate, decamethonium bromide, suxamethonium (chloride, bromide, iodide)).

Calcitriol increases the concentration of magnesium in the blood plasma, calcium preparations reduce the effect of magnesium.

The solution is pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerability).

Overdose

Symptoms: hyperkalemia and hypermagnesemia.

Treatment: intravenous calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

Storage conditions

In a place protected from light, at a temperature of 0–25 °C

Shelf life

2 years

Manufacturer

Biosynthesis, Russia